4.7 Article

Sirtuin 5 promotes arterial thrombosis by blunting the fibrinolytic system

期刊

CARDIOVASCULAR RESEARCH
卷 117, 期 10, 页码 2275-2288

出版社

OXFORD UNIV PRESS
DOI: 10.1093/cvr/cvaa268

关键词

Arterial thrombosis; Sirtuin 5; SIRT5; PAI-1; Cardiovascular disease; Tissue factor

资金

  1. Swiss Heart Foundation
  2. Swiss National Science Foundation [310030_175546, 310030_166576]
  3. Alfred and Annemarie von Sick Grants for Translational and Clinical Research Cardiology and Oncology
  4. European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme [759248]
  5. German Research Foundation [DFG SFB834, 75732319]
  6. H.H. Sheikh Khalifa bin Hamad Al Thani Foundation Assistant Professorship at the Faculty of Medicine, University of Zurich
  7. Swiss National Science Foundation (SNF) [310030_166576] Funding Source: Swiss National Science Foundation (SNF)

向作者/读者索取更多资源

This study demonstrates the important role of SIRT5 in arterial thrombus formation by modulating the activation of the fibrinolysis system through regulating the expression of PAI-1 in endothelial cells. Therefore, SIRT5 may be an interesting therapeutic target in the context of atherothrombotic events.
Aims Arterial thrombosis as a result of plaque rupture or erosion is a key event in acute cardiovascular events. Sirtuin 5 (SIRT5) belongs to the lifespan-regulating sirtuin superfamily and has been implicated in acute ischaemic stroke and cardiac hypertrophy. This project aims at investigating the role of SIRT5 in arterial thrombus formation. Methods and results Sirt5 transgenic (Sirt5(Tg/0)) and knock-out (Sirt5(-/-)) mice underwent photochemically induced carotid endothelial injury to trigger arterial thrombosis. Primary human aortic endothelial cells (HAECs) were treated with SIRT5 silencing-RNA (si-SIRT5) as well as peripheral blood mononuclear cells from acute coronary syndrome (ACS) patients and non-ACS controls (case-control study, total n = 171) were used to increase the translational relevance of our data. Compared to wild-type controls, Sirt5(Tg/0) mice displayed accelerated arterial thrombus formation following endothelial-specific damage. Conversely, in Sirt5(-/-) mice, arterial thrombosis was blunted. Platelet function was unaltered, as assessed by ex vivo collagen-induced aggregometry. Similarly, activation of the coagulation cascade as assessed by vascular and plasma tissue factor (TF) and TF pathway inhibitor expression was unaltered. Increased thrombus embolization episodes and circulating D-dimer levels suggested augmented activation of the fibrinolytic system in Sirt5(-/-) mice. Accordingly, Sirt5(-/-) mice showed reduced plasma and vascular expression of the fibrinolysis inhibitor plasminogen activator inhibitor (PAI)-1. In HAECs, SIRT5-silencing inhibited PAI-1 gene and protein expression in response to TNF-alpha. This effect was mediated by increased AMPK activation and reduced phosphorylation of the MAP kinase ERK 1/2, but not JNK and p38 as shown both in vivo and in vitro. Lastly, both PAI-1 and SIRT5 gene expressions are increased in ACS patients compared to non-ACS controls after adjustment for cardiovascular risk factors, while PAI-1 expression increased across tertiles of SIRT5. Conclusion SIRT5 promotes arterial thrombosis by modulating fibrinolysis through endothelial PAI-1 expression. Hence, SIRT5 may be an interesting therapeutic target in the context of atherothrombotic events.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据